Ginkgo biloba for prevention of dementia: A randomized controlled trial

JAMA

Volumn 300, Issue 19, 2008, Pages 2253-2262

  DeKosky, Steven T ^a,h,i   Williamson, Jeff D ^b   Fitzpatrick, Annette L ^c   Kronmal, Richard A ^c   Ives, Diane G ^a   Saxton, Judith A ^a   Lopez, Oscar L ^a   Burke, Gregory ^b   Carlson, Michelle C ^d   Fried, Linda P ^d   Kuller, Lewis H ^a   Robbins, John A ^e   Tracy, Russell P ^f   Woolard, Nancy F ^b   Dunn, Leslie ^a   Snitz, Beth E ^a   Nahin, Richard L ^g   Furberg, Curt D ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g National Advisory Council for Complementary and Alternative Medicine   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

AGED; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GINKGO BILOBA; HAZARD RATIO; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; VASCULAR DISEASE;

EID: 56649112752     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.683     Document Type: Article

References (49)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337-1342.
2. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von Strauss E, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health. 1998;88(10):1452-1456.
3. Guralnik JM, Leveille SG, Hirsch R, Ferrucci L, Fried LP. The impact of disability on older women. J Am Med Womens Assoc. 1997;52(3):113-120.
4. Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc. 2005;53(2):295-298.
5. Nutritional Business Journal 2006 Supplement Business Report. San Diego, CA: Penton Media Inc; 2006.
6. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol. 1997;29(2):733-742.
7. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002;99(19):12197-12202.
8. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55(11):1409-1415.
9. Birks J, Grimley EV, Van DM. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002;(4):CD003120.
10. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia: North American EGb Study Group. JAMA. 1997;278(16):1327-1332.
11. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hörr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005;2(5):541-551.
12. McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial [published online June 9, 2008]. Int J Geriatr Psychiatry. doi: 10.1002/gps.2055.
13. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29(2):47-56.
14. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology. 2008;70(19 pt 2):1809-1817.
15. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The GuidAge study: methodological issues: a 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology. 2006;67(9)(suppl 3):S6-S11.
16. DeKosky ST, Fitzpatrick A, Ives DG, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials. 2006;27(3):238-253.
17. Fitzpatrick AL, Fried LP, Williamson J, et al. Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials. 2006;27(6):541-553.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
20. Snitz BE, Saxon J, Lopez OL, et al. Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) Study. Aging Ment Health. 2009;13(2). In press.
21. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246.
22. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res. 1997;31(6):645-655.
23. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22(1):1-12.
24. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314-318.
25. Mohs RC. The Alzheimer's Disease Assessment Scale. Int Psychogeriatr. 1996;8(2):195-203.
26. Becker JT, Boller F, Saxton J, Gonigle-Gibson KL. Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex. 1987;23(1):59-72.
27. Delis DC. California Verbal Learning Test. New York, NY: Psychological Corp; 1987.
28. Grober E, Sliwinski M. Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J Clin Exp Neuropsychol. 1991;13(6):933-949.
29. Lopez OL, Becker JT, Jagust WJ, et al. Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry. 2006;77(2):159-165.
30. Raven JC. Guide to Using the Coloured Progressive Matrices. London, England: HK Lewis; 1956.
31. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393-394.
32. Saxton J, Ratcliff G, Munro CA, et al. Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol. 2000;14(4):526-534.
33. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York, NY: Oxford University Press; 1998.
34. Trenerry MR, Crosson B, DeBoe J, Lever WR. STROOP Neuropsychological Screening Test. Odessa, FL: Psychological Assessment Resources; 1989.
35. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corp; 1988.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
37. Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia. 1994;5(3-4):189-192.
38. Rockwood K, Parhad I, Hachinski V, et al. Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research consensus statement. Can J Neurol Sci. 1994;21(4):358-364.
39. Chui HC, Mack W, Jackson JE, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol. 2000;57(2):191-196.
40. Fleming TR, Harrington D, O'Brien P. Designs for group sequential tests. Control Clin Trials. 1984;5(4):348-361.
41. Auguet M, DeFeudis FV, Clostre F. Effects of Ginkgo biloba on arterial smooth muscle responses to vasoactive stimuli. Gen Pharmacol. 1982;13(2):169-171.
42. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci. 2000;12(6):1882-1890.
43. Brunetti L, Orlando G, Menghini L, Ferrante C, Chiavaroli A, Vacca M. Ginkgo biloba leaf extract reverses amyloid beta-peptide-induced isoprostane production in rat brain in vitro. Planta Med. 2006;72(14):1296-1299.
44. Chen X, Salwinski S, Lee TJ. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol. 1997;24(12):958-959.
45. Kawas CH, Brookmeyer R. Aging and the public health effects of dementia. N Engl J Med. 2001;344(15):1160-1161.
46. Mahady GB. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J Cardiovasc Nurs. 2002;16(4):21-32.
47. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun. 1994;201(2):748-755.
48. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
49. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.